Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Reuters NewMedia - October 13, 2008
Barbara Hogan in September replaced Manto Tshabalala-Msimang when President Kgalema Motlanthe took over from Mbeki as head of state and formed a new cabinet. The comments on Monday were her most critical yet of the Mbeki government's stance on HIV.
"... It was imperative to get ahead of the curve of this epidemic ten years ago. We all, for various reasons, have lost ground," Hogan told the opening ceremony of an AIDS Vaccine conference in Cape Town.
"We also wasted time despite having one of the best plans to cope with the epidemic," she said, adding South Africa must now show more urgency in implementing a national programme launched last year to fight HIV/AIDS.
Mbeki drew sharp criticism shortly after coming to power in 1999 when he questioned accepted AIDS science and failed to make life-prolonging anti-retroviral drugs (ARVs) widely available. Tshabalala-Msimang has been lampooned by leading scientisis and activists for recommending garlic and beetroot as treatments.
Some 900 scientists and policy-makers are in Cape Town to debate developments in the hunt for an AIDS vaccine.
Almost 25 years after HIV was identified as the cause of AIDS, killing an estimated 23 million people in the interim, scientists working on discovering an effective vaccine are at a crossroads after two major vaccine prototypes were discontinued late last year due to safety concerns.
This was a major blow in the global drive to combat AIDS, with some 33 million people currently living with the disease according to the United Nations, despite better education campaigns and newer ARV drugs.
"At the end of the day we're not going to get a vaccine just with money... This requires long-term political support," Dr Alan Bernstein, the executive director of conference hosts, the Global HIV Vaccine Enterprise, told reporters. (Reporting by Wendell Roelf; Editing by Louise Ireland)
081013
RE081018
Copyright © 2008 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .